Please login to the form below

Not currently logged in

Industry frustrated by late warning on 'no deal' Brexit disruption

Dover and Folkestone could have 6 months of disruption

UK life sciences gets some Brexit relief with £1.3bn sector deal

Highlights commitments from Roche, IQVIA, Celgene and Autolus

Genomics England reaches 100,000th genome sequencing milestone

Genomics EnglandUK becomes world first to introduce whole genomic sequencing in clinics

Triple defeat puts May’s Brexit deal up against the wall

Theresa MayProspects of a no-deal Brexit seems to loom ever larger

UK pharma Brexit pessimism deepens, as govt admits sector could be among worst hit

Political gridlock fuels fears ahead of 11 Dec vote

Medical devices probe uncovers need for “drastic regulatory changes”

ICIJReport uncovers lax European regulatory system for medical devices

As Brexit looms, UK medicines agency head Hudson announces departure

MHRASearch for successor must start in early 2019

Reference price bill tabled in US House and Senate

The new measure could reduce median drug prices by around 43%

The shifting healthcare landscape

Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...